Investor Relations
NanoMedex’s positioning thesis is centered on potential synergies and growth potential for a prospective investor or prospective buyer.
NanoMedex Overall Corporate Strategy:
Elements of the corporate strategy include the following:
- Development of a robust product pipeline (i.e., other generic drugs and drug categories) which will lead to significant clinical benefit and growth potential.
- International market expansion on a product-by-product strategy.
- Defensible patent portfolio.
- Scalable growth platform. The company’s focus on internal developmental chemistry with outsource execution of all other activities allows for minimal overhead and parallel product development strategies.
- Establish development processes to optimize speed to market. Development of new microemulsion formulations of generic drugs promises 3-4 year execution times from concept to FDA approval.
- 505(b)(2) process supporting approval speed.
Corporate History
Corporate Profile:
NanoMedex Pharmaceuticals, Inc. (NMDX) was formed in 2002 in the State of Delaware. The founders include four, currently practicing physician-scientists (Donn M. Dennis, M.D., Nikolaus Gravenstein, M.D., Jerome H. Modell, M.D., Timothy E. Morey, M.D.), a chemical engineer (Dinesh O. Shah, Ph.D.), and a experienced venture investor (Kenneth U. Johnson).
A NIH SBIR Phase I grant was submitted in December, 2003 that was successful in application and execution which led to a successful Phase II grant application and award in 2005. Successful execution of this Phase II SBIR was completed in 2008 combined with private investment funding allowed NMDX to engage regulatory counsel to develop the 505(b)(2) approval pathway strategy.
NanoMedex applied and was successful in being awarded Qualified New Business Venture Certification by the Department of Commerce, State of Wisconsin. Therefore in September 2008 NMDX moved to Fitchburg, Wisconsin. Included in this award were the Angel Investment and Venture Capital Tax Credit program designed to encourage investment in small, high-technology businesses that have high growth potential. Additionally, NanoMedex was awarded a Technology Bridge Grant, Technology Venture Fund Grant and Technology Assistance Grant.
NanoMedex has successfully completed its second round of funding through the lead of Kegonsa Capital Partner and its Limited Partners.
